News
Quantum Genomics Announces Granting of New Patents Protecting QGC606
Quantum Genomics Announces Granting of New Patents Protecting QGC606
Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new
QUANTUM GENOMICS : Stéphane Cohen joins Quantum Genomics as Director of Global Operations
Stéphane Cohen joins Quantum Genomics as Director of Global Operations
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new
BOIRON : 2021 results
The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31
THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
- · New milestone for NeuroLead, the active agent screening platform
- · New publications in scientific journals
- · Start of Phase I/II clinical trial for Batten disease
Lyon, 28 February 2022
THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS
Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates
BOIRON : 2021 sales
(Unaudited data)
QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)
in thousands of euros 1st quarter 2nd quarter 3rd quarter 4th quarter 2021 2020 Var. 2021THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022
Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.
Press release
Paris, December 6, 2021
Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.
- Quantum Genomics will receive up to $20 M
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
Press release
Paris, November 25, 2021
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
- Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30%
QUANTUM GENOMICS : Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences
Press release
Paris, November 23, 2021
Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences
Quantum Genomics (Euronext Growth : ALQGC, OTCQX
Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
Valbiotis meldet auf der Jahrestagung der American Heart Association (AHA) positive präklinische Ergebnisse für TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris: ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211114005021/en/
TOTUM•070 preclinical results AHA 2021 (Graphic
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for
Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:
Sensorion to present in person at “Jefferies London Healthcare Conference”
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Transgene Reports Business Update and Q3 2021 Financial Position
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will